Attached files
| file | filename |
|---|---|
| EX-10.14 - EX-10.14 - Relay Therapeutics, Inc. | d132252dex1014.htm |
| EX-10.10 - EX-10.10 - Relay Therapeutics, Inc. | d132252dex1010.htm |
| EX-10.5 - EX-10.5 - Relay Therapeutics, Inc. | d132252dex105.htm |
| EX-5.1 - EX-5.1 - Relay Therapeutics, Inc. | d132252dex51.htm |
| S-1 - S-1 - Relay Therapeutics, Inc. | d132252ds1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-1) and related Prospectus of Relay Therapeutics, Inc. for the registration of 1,883,487 shares of its common stock and to the incorporation by reference therein of our report dated March 25, 2021, with respect to the consolidated financial statements of Relay Therapeutics, Inc. included in its Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission.
| /s/ Ernst & Young LLP |
| Boston, Massachusetts |
| April 28, 2021 |